Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully

December 06, 2023 06:24 AM PST | By Invezz

Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully — Image source: Invezz

CMND was trading at $100 before bleeding to the current price

It is essential to highlight that CMND traded at prices above $100 until April this year. From that point, the stock plummeted to its current lows. Investors who lost market capital probably hope the stock will rise soon. However, there is no indication that the stock will rally to its former glory soon. At least not when the company has yet to get the licence to test its products on people. Until then, CMND is a stock that serious investors and traders must avoid like a plague.

CMND is simply the goose that got cooked. Positive vibes about a drug that cures cocaine addiction are noble but of little investment value. The company must offer the market information about real milestones in developing the drug. The only information that can change our views is news from large sample randomised clinical trials. Until then, we strongly recommend against buying CMND.

Summary

The positive news about CMND is just a smoke screen. The market should only take the news seriously once the company offers tangible results. Investors should wait for results from RCT trials. Until then, CMND is a cooked goose, as the stock risks remain.

The post Clearmind Medicine Inc (CMND) is the goose that got cooked - trade carefully appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.